CORDIS
EU research results

CORDIS

English EN
High Throughput Proteomics Systems for Accelerated Profiling of Putative Plasma Biomarkers

High Throughput Proteomics Systems for Accelerated Profiling of Putative Plasma Biomarkers

Objective

The PROACTIVE consortium will through research and innovation develop the multiplexed proximity ligation assay into a high throughput protein detection and quantification technology along with novel data management and analysis tools. Hundreds of putative biomarkers of the plasma proteome can then be assayed with high sensitivity in minute sample volumes, far surpassing any current capabilities. This consortium combines three SMEs across Europe with synergistic competences in technology development, reagent manufacturing, and software development for data management and analysis. Together with clinical cancer scientists, biostatisticians, and diagnostics industry, these high capacity tools will be evaluated in pilot projects for cancer biomarkers using biobanked samples. Preliminary data in the literature claim improved diagnostics with the use of multiple complementary protein markers. However, there is a lack of suitable high throughput procedures for finding new markers and discovering which markers complement each other into effective diagnostic panels. Better capabilities to diagnose cancer at the early and most curable stages will greatly improve human health and reduce health care costs. Patient stratification is also in need of better diagnostics to facilitate the selection of appropriate patient care. Many clinically used immunoassays capable of diagnosing cancer have been in use for many years as single markers but with limited sensitivity and specificity. No marker can today single-handedly diagnose all cases with desired accuracy for a certain cancer type. Also, the performance of these markers is decreased for the earliest stages of the disease. At the conclusion of this collaborative project, the research and innovation conducted within the consortium will enable the partners to position themselves at the very fore-front of high-throughput biomarker research strengthening their competitiveness in the international arena.

Coordinator

MOLECULINK AB

Address

Chemistry Bmc - Box 599
751 24 Uppsala

Sweden

Activity type

Private for-profit entities (excluding Higher or Secondary Education Establishments)

EU Contribution

€ 1 075 800

Administrative Contact

Simon Fredriksson (Dr.)

Participants (5)

Sort alphabetically

Sort by EU Contribution

Expand all

INNOVA BIOSCIENCES LIMITED

United Kingdom

EU Contribution

€ 448 200

UPPSALA UNIVERSITET

Sweden

EU Contribution

€ 283 200

INTEGROMICS SL ITG

Spain

EU Contribution

€ 387 000

KOBENHAVNS UNIVERSITET

Denmark

EU Contribution

€ 736 800

FUJIREBIO DIAGNOSTICS AB

Sweden

EU Contribution

€ 58 800

Project information

Grant agreement ID: 222950

Status

Closed project

  • Start date

    1 October 2008

  • End date

    30 September 2011

Funded under:

FP7-HEALTH

  • Overall budget:

    € 3 950 800

  • EU contribution

    € 2 989 800

Coordinated by:

MOLECULINK AB

Sweden